Champions Oncology

What Champions Oncology does

Champions Oncology is a translational oncology Contract Research Organization (CRO) that develops and commercializes patient-derived xenograft (PDX) models and integrated multi-omic data products to support oncology drug development. The company maintains a TumorGraft platform comprising over 1,400 patient-derived and primary hematological models implanted in immunodeficient mice, with each model annotated by what the company describes as the world's most comprehensive curated multi-omics molecular dataset exceeding 2 billion data points spanning whole-exome sequencing, RNA-seq, proteomics, cell surface, and functional readouts. Its product surface includes Mouse Clinical Trials (PDX-based clinical trial simulation), TumorGraft3D ex vivo organoid models, humanized and syngeneic immuno-oncology models, a Radiopharmaceutical Testing Platform, and the Lumin bioinformatics SaaS platform for tumor genetics and therapeutic response analysis. A wholly owned subsidiary, Corellia AI, focuses on AI-enabled therapeutic development workflows.

Champions generates revenue primarily through fee-for-service preclinical and clinical specialty studies sold to pharmaceutical and biotechnology companies, with typical studies priced in the $100,000 range and an increasing number of larger programs priced between $250,000 and $500,000. A second revenue stream, data licensing, monetizes the multi-omic dataset linked to PDX models, with the inaugural deal reported in fiscal Q3 2025. Tumor model licensing from the TumorBank constitutes a third, smaller stream. The company deploys a direct enterprise sales force of 27 professionals targeting large pharma and oncology-focused biotech, supported by scientific marketing through AACR presentations, an annual Translational Oncology Symposium, webinars, case studies, and the Lumin platform itself as a customer-engagement surface.

Champions is publicly listed on Nasdaq (ticker: CSBR), headquartered in Hackensack, New Jersey, with research operations in Rockville, Maryland and a bioinformatics/computational biology presence in Ramat Gan, Israel. It serves more than 500 pharmaceutical and biotechnology customers cumulatively over the past eight years. The company has reported consecutive quarters of positive adjusted EBITDA through Q3 FY2026, including $574,000 in that quarter, and has grown study services revenue at a 32% CAGR since 2015.

Name

Champions Oncology

Legal name

Champions Oncology, Inc.

Website

https://championsoncology.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Champions Oncology is a translational oncology CRO that sells patient-derived xenograft (PDX) models, multi-omic data, and preclinical/clinical specialty testing services to pharmaceutical and biotechnology companies developing cancer drugs.

Ownership category

akta.pro rank

Product category

Preclinical Oncology CRO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Oncology Specialty Pharmaceuticals (HLAIACAA), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Oncology preclinical research
• Patient-derived xenograft models
• Translational oncology services
• Oncology multi-omic data
• Radiopharmaceutical testing services

Headquarters

HQ city

Hackensack

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Study Services Revenue: Core revenue stream from preclinical and clinical studies using PDX models. Studies are priced typically in the $100,000 range with increasing number of studies in the $250,000 to $500,000 range. Q3 FY2026 reported record study service revenue of $16.6 million, a 32% increase year over year.
2. Data Licensing: New data licensing business leveraging deep multiomic PDX tumor model data. Champions reported its inaugural data licensing deal and record adjusted EBITDA of $5.2 million in Q3 FY2025. The company has multiple prospects in the pipeline for this revenue stream.
3. Tumor Model Licensing: License of tumors from TumorBank for use in studies by pharmaceutical and biotechnology companies

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Champions Oncology provides contract research services for oncology drug development centered on patient-derived xenograft (PDX) models and complementary ex vivo and in vivo preclinical platforms, integrated with clinical specialty testing (flow cytometry, NGS, proteomics) and the Lumin bioinformatics SaaS. Customers buy preclinical studies, mouse clinical trial simulations, and data licensing against a multi-omic TumorBank of more than 1,400 models with over 2 billion data points.

Product overview

Champions Oncology is a translational oncology research organization offering an integrated platform combining preclinical in vivo models with clinical specialty testing services and a proprietary multi-omic data ecosystem. The core offering centers on Patient-Derived Xenograft (PDX) models (over 1,400 models), which are complemented by the TumorGraft3D ex vivo platform, Mouse Clinical Trials simulation service, and the Lumin bioinformatics platform for data analysis. The company provides comprehensive assay services including Next Generation Sequencing, Flow Cytometry, and 4D Proteomics, alongside specialized offerings in radiopharmaceutical testing and hematological malignancies. The portfolio is unified through Champions' data ecosystem, which integrates WES, RNA-seq, proteomics, and functional data linked to PDX models. The wholly owned subsidiary Corellia AI focuses on AI-enabled therapeutic development. Services are delivered through direct sales to pharmaceutical and biotechnology companies globally.

Differentiator

Problem solved

Functional benefit

Brands

• Lumin: Champions Oncology's bioinformatics platform providing researchers with comprehensive, real-time insights into tumor genetics and therapeutic responses, featuring multi-omic dataset analysis and visualization.
• Corellia AI (Corellia)

Products and services

• Patient-Derived Xenograft (PDX) Models Champions' flagship preclinical in vivo models derived from human tumor tissue implanted in immunodeficient mice. The TumorBank of over 1,400 models with layered multi-omic data provides clinically relevant models for drug efficacy testing and response prediction in oncology drug development for pharmaceutical and biotechnology customers.
• Lumin Bioinformatics Platform Champions Oncology's proprietary SaaS bioinformatics platform providing researchers with comprehensive, real-time insights into tumor genetics and therapeutic responses via multi-omic dataset analysis and visualization, supporting data-driven decisions and improved clinical outcomes for pharma and biotech R&D teams.
• Mouse Clinical Trials Clinical trial simulation service using Champions' PDX models to predict drug efficacy in human patients, enabling informed go/no-go decisions before initiating human oncology trials for pharma and biotech drug developers.
• TumorGraft3D Models Three-dimensional patient-derived tumor model platform enabling ex vivo drug screening and validation of therapeutic candidates in a more physiologically relevant environment for oncology drug developers.
• Radiopharmaceutical Testing Services Preclinical radiopharmaceutical development services combining Champions' clinically relevant PDX models with radiopharmaceutical development capabilities for targeted cancer therapy validation, including radiolabeled ADCs and biologics.
• Next Generation Sequencing (NGS) Services Comprehensive genomic sequencing services including whole-exome sequencing (WES), RNA-seq, and targeted panels to characterize tumor models and support biomarker discovery for oncology research programs.
• Flow Cytometry Services GCLP High Complexity Flow Cytometry services for comprehensive cellular analysis in preclinical and clinical oncology studies.
• Humanized PDX Models PDX models engineered to support engraftment of functional human immune system components, enabling immuno-oncology research and evaluation of immunotherapeutic agents.
• Syngeneic Models Preclinical in vivo models using mice with complete functional immune systems for evaluating therapeutic candidates in immunocompetent hosts.
• Cell Surface Proteomics Data Proprietary proteomics data product within Champions' data ecosystem providing cell surface protein expression data linked to PDX models for target discovery and validation in oncology research.
• Pretreated PDX Models PDX models derived from patients who have received prior treatments, reflecting the clinical reality of late-stage, pretreated metastatic cancer for more relevant drug testing.
• Hematological Malignancies Models Blood cancer models including hematological PDX models and the Hematological VitroScreen platform for leukemia and lymphoma drug testing.
• 4D Proteomics Services Advanced proteomics services providing comprehensive protein expression and modification analysis to support oncology research programs.
• DNA Damage Assays Analytical assays to evaluate DNA damage and repair mechanisms in tumor models, supporting research on DNA-targeting cancer therapeutics.
• Ex Vivo Platforms Patient-derived ex vivo testing platforms including 3D solid tumor screens, co-culture assays, and blood cancer screens enabling drug efficacy testing outside of living organisms.
• Early Drug Discovery Solutions Comprehensive early-stage oncology drug discovery services leveraging Champions' integrated platform of models, assays, and data to accelerate hit-to-lead optimization for pharmaceutical and biotechnology customers.
• Corellia AI Wholly owned biotech subsidiary of Champions Oncology that applies unique AI-enabled workflows and Champions' proprietary multi-omic PDX tumor model data to novel therapeutic development.

Quantifiable outcome

• Approximately 87% positive predictive value and 94% negative predictive value in predicting drug response
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• TurbinecoreStrategic or Co-development Partner · 24 April 2025Strategic collaboration to advance Champions Oncology's data platform capabilities. Turbine brings computational biology and simulation capabilities to enhance the multi-omic data ecosystem.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 16 October 2024Strategic collaboration with Weill Cornell Medicine to advance translational oncology research. Champions announced agreement to collaborate on research programs.
• Medicines Discovery CatapultcoreStrategic or Co-development Partner · 4 June 2024Partnership to accelerate radiopharmaceutical therapeutics development. Combines Champions' PDX models with Medicines Discovery Catapult's capabilities in drug discovery.
• GigaMuneminorStrategic or Co-development Partner · 15 February 2022Partnership to discover novel tumor-reactive T cell receptors leveraging Champions' PDX models and tumor data.
• Fannin InnovationminorStrategic or Co-development Partner · 20 January 2022Joint development partnership to develop therapeutic Raptamer drug conjugates using Champions' preclinical platforms.
• Alloy TherapeuticsminorStrategic or Co-development Partner · 4 January 2022Partnership to develop therapeutic monoclonal antibodies for use in ADC programs leveraging Champions' PDX models.
• Children's Cancer Therapy Development InstituteminorStrategic or Co-development Partner · 29 January 2020Collaboration with Jackson Laboratory to provide RACEact/PREA Pediatric Cancer Study Plan Services for pediatric oncology research.

Scale indicators11 records

Recent moves1 record

Expansion highlights6 records

Direct peers

• Crown Bioscience: Crown Bioscience is a JSR Life Sciences subsidiary that operates one of the largest commercial PDX tumor model libraries and offers preclinical oncology CRO services — directly competing with Champions' PDX-based preclinical platform and study services for pharma and biotech customers.
• Inotiv: Inotiv provides preclinical contract research services including toxicology, pharmacology, and animal models for drug development, with oncology-relevant in vivo capabilities; it competes with Champions for preclinical oncology study work but lacks the same PDX + multi-omic data integration.
• Xentech: Xentech is a French preclinical oncology CRO specializing in patient-derived tumor xenograft models and translational research services for pharma and biotech; it directly competes with Champions' PDX and TumorGraft platform for European and US preclinical oncology contracts.

Broad incumbents

• Charles River Laboratories: Charles River is a large preclinical and clinical CRO with a dedicated oncology and discovery services portfolio including in vivo pharmacology and patient-derived models; it competes with Champions for enterprise preclinical study budgets while offering broader safety, manufacturing, and CDMO capabilities.
• Wuxi AppTec: Wuxi AppTec is a global CRO/CDMO with preclinical and clinical oncology capabilities, including in vivo pharmacology and biomarker services; it serves overlapping pharma and biotech customers as Champions but at materially larger scale and with a broader end-to-end service offering.
• Labcorp: Labcorp's early development and central laboratory services include preclinical and translational oncology offerings; as a broad diagnostics and drug development incumbent, it overlaps with Champions' clinical specialty testing and bioanalytical services rather than its core PDX platform.
• Medpace: Medpace is a mid-sized clinical CRO with strong oncology franchise; while primarily clinical-stage, it competes for oncology R&D budgets and provides bioanalytical and biomarker capabilities that overlap with Champions' clinical specialty testing services.
• Pharmaron: Pharmaron is a global CRO/CDMO offering preclinical in vivo pharmacology, DMPK, and safety assessment services including oncology-relevant models; it competes for preclinical oncology study work with broader integrated drug discovery capabilities than Champions.

Emerging players

• Personalis: Personalis is a genomic sequencing and multi-omic data company focused on oncology drug development and clinical trial support; it competes with the data licensing and multi-omic analytics components of Champions' Lumin platform rather than its in vivo PDX services.
• Tempus AI: Tempus AI is a data-driven precision medicine company providing multi-omic profiling, molecular data, and AI analytics for oncology research and clinical trials; it is an emerging player that intersects with Champions' Lumin bioinformatics and data licensing offerings rather than its in vivo PDX services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/champsonco
• Facebookfacebook.com/championsoncology
• LinkedInlinkedin.com/company/champions-oncology-inc-/mycompany
• Instagraminstagram.com/championsoncology

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Champions Oncology